Crescent Energy Company Class A Common Stock vs Heron Therapeutics Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.66 (market cap $4.30B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Crescent Energy Company Class A Common Stock is far larger — about 63.2× Heron Therapeutics Inc's market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Heron Therapeutics Inc for 35 Days on average.
| CRGY | HRTX | |
|---|---|---|
Market Cap | $4.30B | $68.01M |
Volume | 15,201,625 | 1,891,941 |
Sector | Energy | Health |
52-Week High | $15.37 | $1.49 |
52-Week Low | $7.75 | $0.27 |
Typical Hold Time | 1 Days | 35 Days |
Enterprise Value | $9.31B | $174.75M |
Dividend Yield | 3.69% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →